481 related articles for article (PubMed ID: 15184247)
1. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
2. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
[TBL] [Abstract][Full Text] [Related]
3. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
5. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical characteristics of duodenal adenomas in familial adenomatous polyposis with special reference to cell kinetics.
Esaki M; Matsumoto T; Yao S; Nakamura S; Hirahashi M; Yao T; Iida M
Hum Pathol; 2005 Jan; 36(1):66-73. PubMed ID: 15712184
[TBL] [Abstract][Full Text] [Related]
8. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas.
Martin C; Connelly A; Keku TO; Mountcastle SB; Galanko J; Woosley JT; Schliebe B; Lund PK; Sandler RS
Gastroenterology; 2002 Dec; 123(6):1770-7. PubMed ID: 12454832
[TBL] [Abstract][Full Text] [Related]
11. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Brosens LA; Iacobuzio-Donahue CA; Keller JJ; Hustinx SR; Carvalho R; Morsink FH; Hylind LM; Offerhaus GJ; Giardiello FM; Goggins M
Clin Cancer Res; 2005 Jun; 11(11):4090-6. PubMed ID: 15930344
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
13. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
[TBL] [Abstract][Full Text] [Related]
15. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.
Keller JJ; Offerhaus GJ; Drillenburg P; Caspers E; Musler A; Ristimäki A; Giardiello FM
Clin Cancer Res; 2001 Dec; 7(12):4000-7. PubMed ID: 11751493
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
